Iantrek
Iantrek is a private medical device company that develops bio-interventional and micro-interventional ophthalmic surgical devices — AlloFlo Uveo, AlloSert Uveo, and C-Rex — for minimally invasive glaucoma surgery targeting uveoscleral and trabecular outflow pathways, sold to ophthalmologists and glaucoma surgeons in the United States.
- Company typePrivate
- Founded2019
- HeadquartersWhite Plains, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Iantrek does
Iantrek is a private medical technology company headquartered in White Plains, New York, that develops bio-interventional and micro-interventional ophthalmic surgical devices for the treatment of glaucoma. The company's commercial platform comprises three core products: AlloFlo Uveo, an acellular homologous scleral allograft bio-tissue spacer that reinforces the uveoscleral pathway to enhance aqueous outflow without damaging the conjunctiva or requiring implantable hardware; AlloSert Uveo, an ambidextrous surgical delivery instrument that enables controlled cyclodialysis and precise positioning of the AlloFlo Uveo dual bio-spacers; and C-Rex, a single-use disposable super-elastic Nitinol device for ab-interno transluminal canaloplasty and inner wall trabeculotomy, capable of 360-degree circumferential tracking in a single continuous motion. The platform is supported by the CREST clinical study (500+ eyes across 16 locations, 7 peer-reviewed publications) demonstrating 32–40% mean IOP reduction and 40–64% mean medication reduction at 12–24 months with sub-0.5% clinical hypotony rates.
Iantrek operates as a medical device manufacturer generating revenue through hardware and bio-tissue sales to ophthalmologists and glaucoma surgeons. Pricing is not publicly disclosed; transactions follow the standard institutional medtech quoting model. The go-to-market is enterprise field sales with a 'Contact a Rep' / 'Book a Demo' model targeting hospital and ambulatory surgical center accounts, supplemented by peer-reviewed publications, medical conference presence (ASCRS, AAO, AGS, Glaucoma 360, AECOS), surgeon testimonials, and a 'Find a Surgeon' patient-referral directory. The primary customer segment is MIGS-performing ophthalmologists and glaucoma specialists in the United States.
The company is venture-backed, having raised approximately $100 million cumulatively across a Series A (2020), Series B (2022), Series C (2025), and a 2026 debt facility. AlloFlo Uveo was commercially launched in October 2025 following 3,000+ prior U.S. cases and 100+ trained surgeons, with a development pipeline extending the platform into additional uveoscleral and trabecular indications. AlloFlo Uveo is regulated under Section 361 of the Public Health Services Act. The company employs 51–100 people and is led by CEO Adam Szaronos (appointed February 2025) with founder Dr. Sean Ianchulev serving as Chairman and Chief Medical Officer.
Iantrek firmographics
Firmographics- Name
- Iantrek
- Legal name
- Iantrek, Inc.
- Website
- https://iantrekmed.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Iantrek is a private medical device company that develops bio-interventional and micro-interventional ophthalmic surgical devices — AlloFlo Uveo, AlloSert Uveo, and C-Rex — for minimally invasive glaucoma surgery targeting uveoscleral and trabecular outflow pathways, sold to ophthalmologists and glaucoma surgeons in the United States.
- Ownership category
- akta.pro rank
Iantrek industry classification
Industry- Product category
- Ophthalmic Surgical Devices (Minimally Invasive Glaucoma Surgery)
- NAICS
- Ophthalmic Goods Manufacturing (339115), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty) (HLAHAJAI)
- akta.pro secondary industry
- Glaucoma Specialists (HLAKAKAG)
Keywords
Where Iantrek is headquartered
LocationHeadquarters
- HQ city
- White Plains
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Iantrek business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Surgical Device Sales: Iantrek generates revenue through the sale of its commercialized surgical products including AlloFlo Uveo and AlloSert Uveo to ophthalmologists and hospitals. The company operates as a medical device manufacturer selling directly to healthcare providers for use in glaucoma surgical procedures.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Iantrek product offering
Product offeringCore offering
Iantrek develops and commercializes bio-interventional and micro-interventional ophthalmic surgical devices used by ophthalmologists and glaucoma surgeons in minimally invasive glaucoma surgery. Its core offerings are AlloFlo Uveo (a dual bio-spacer homologous scleral allograft for uveoscleral outflow enhancement), AlloSert Uveo (the surgical delivery instrument for AlloFlo Uveo enabling controlled cyclodialysis), and C-Rex (a single-use Nitinol device for combined canaloplasty and goniotomy). The devices are sold directly to healthcare providers and hospitals in the United States for use in glaucoma surgical procedures.
Product overview
Iantrek is a medical technology company specializing in bio-interventional ophthalmic surgery for glaucoma treatment. The product portfolio centers on three commercially available surgical devices: AlloFlo Uveo (a bio-tissue spacer technology for uveoscleral outflow enhancement), AlloSert Uveo (the delivery instrument for AlloFlo Uveo that enables controlled cyclodialysis), and C-Rex (a micro-interventional device combining canaloplasty and goniotomy using super-elastic Nitinol). AlloFlo Uveo and AlloSert Uveo work together as a system targeting the uveoscleral pathway, while C-Rex targets the trabecular/Schlemm's canal pathway. The pipeline includes AlloSpan Canal and C-Rex Duo for additional glaucoma intervention approaches.
Differentiator
Problem solved
Functional benefit
Brands
- AlloFlo Uveo: Bio-interventional outflow enhancement device through the uveoscleral pathway, a surgical device for glaucoma treatment.
- AlloSert Uveo
- C-Rex
Products and services
- AlloFlo Uveo Bio-tissue spacer technology for uveoscleral outflow enhancement in glaucoma treatment, using acellular homologous scleral allograft tissue to provide scaffolding, bio-reinforcement, and maintenance of the aqueous pathway via dual bio-spacers during cyclodialysis; intended for ophthalmologists and glaucoma surgeons performing MIGS procedures.
- AlloSert Uveo Surgical instrument used for ab-interno construction or modification of a cyclodialysis followed by delivery of bio-tissue/allograft to reinforce and maintain the cyclodialysis cleft; serves as the dedicated delivery system for AlloFlo Uveo and features an ergonomic, ambidextrous design with empty or pre-loaded carrier tip options.
- C-Rex Single-use disposable manual ophthalmic surgical instrument for ab-interno transluminal dilation (canaloplasty) and inner wall trabeculotomy (goniotomy); uses super-elastic Nitinol for smooth circumferential tracking up to 360 degrees with clock-hour demarcations for precise filament advancement feedback.
Quantifiable outcome
- 32-40% mean IOP reduction at 12-24 months post-surgery
- +4 more outcomes
Companies that use Iantrek
Customer profileNamed customers8 records
Segments1 record
Ideal customer profiles1 record
Iantrek technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Iantrek partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Adam SzaronoscoreAdam Szaronos appointed as CEO of Iantrek. Serves as Board Member alongside his executive leadership role.
Scale indicators5 records
Recent moves6 records
Expansion highlights3 records
Iantrek competitors and assessment
Company assessmentBroad incumbents
- Alcon: Alcon is a global ophthalmic incumbent that markets the Hydrus Microstent and offers a broad surgical glaucoma portfolio. It competes with Iantrek across the MIGS category and brings substantially greater commercial scale and surgeon access.
- Bausch + Lomb: Bausch + Lomb is a large incumbent ophthalmic medical device and pharmaceutical company with a presence in surgical glaucoma. It is a broad incumbent competing in the same surgeon call point with greater resources and breadth.
Emerging players
- Belkin Vision: Belkin Vision has developed the Eagle direct selective laser trabeculoplasty device for glaucoma. It is an emerging player offering a non-incisional interventional approach to the same ophthalmologist customer base Iantrek targets.
- Sanoculis: Sanoculis developed the MIMS (Minimally Invasive Micro Sclerostomy) procedure for glaucoma. It is an emerging player with a novel surgical approach to the same glaucoma interventional market that Iantrek addresses.
- iSTAR Medical: iSTAR Medical developed the MINIject suprachoroidal glaucoma implant, targeting uveoscleral/suprachoroidal outflow. It is an emerging player with direct overlap in the uveoscleral mechanism that Iantrek is also pursuing.
- MicroOptx: MicroOptx is developing novel micro-invasive glaucoma surgical approaches. As a small, early-stage MIGS innovator, it is comparable to Iantrek in stage and category focus on interventional outflow enhancement.
Direct peers
- New World Medical: New World Medical develops and distributes surgical devices for glaucoma, including the Kahook Dual Blade for goniotomy. It is a direct peer in interventional glaucoma surgical devices aimed at ophthalmic surgeons.
- Sight Sciences: Sight Sciences markets the OMNI Surgical System, which combines canaloplasty and trabeculotomy for glaucoma treatment. It is a direct peer in MIGS device design, physician call point, and the procedural category Iantrek's C-Rex also targets.
- Glaukos Corporation: Glaukos pioneered the MIGS category with its iStent devices for trabecular outflow enhancement. It is the most direct competitor to Iantrek in interventional glaucoma surgery, serving the same ophthalmologist customer base with a complementary outflow pathway focus.
- Nova Eye Medical: Nova Eye Medical markets the iTrack canaloplasty device targeting the trabecular pathway. It is a direct peer in canaloplasty-based MIGS, addressing the same glaucoma surgeon customer with a similar minimally invasive, outflow-focused approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Iantrek social profiles
Digital presenceIantrek financial estimates
Financial estimateRevenue estimate
Valuation estimate
Iantrek leadership team
Management profileNumber of profiles
Profiles3 records
Iantrek funding detail
Funding detailFunding overview
Funding rounds4 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Iantrek M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Iantrek
What does Iantrek do?
Iantrek develops and commercializes bio-interventional and micro-interventional ophthalmic surgical devices used by ophthalmologists and glaucoma surgeons in minimally invasive glaucoma surgery. Its core offerings are AlloFlo Uveo (a dual bio-spacer homologous scleral allograft for uveoscleral outflow enhancement), AlloSert Uveo (the surgical delivery instrument for AlloFlo Uveo enabling controlled cyclodialysis), and C-Rex (a single-use Nitinol device for combined canaloplasty and goniotomy). The devices are sold directly to healthcare providers and hospitals in the United States for use in glaucoma surgical procedures.
Is Iantrek a public or private company?
Iantrek is a private company. It is classified as venture growth investor backed and is currently operating.
When was Iantrek founded?
Iantrek was founded in 2019. It employs 51 to 100 people.
Where is Iantrek based?
Iantrek is headquartered in White Plains, United States, in the North America region.
How does Iantrek make money?
One revenue line is on record: surgical Device Sales.
Who are Iantrek's main competitors?
Broad incumbents on record are Alcon and Bausch + Lomb. Emerging players are Belkin Vision, Sanoculis, iSTAR Medical and MicroOptx. Direct peers are New World Medical, Sight Sciences, Glaukos Corporation and Nova Eye Medical.
Does Iantrek have an API?
No public API is recorded for Iantrek.
What industry is Iantrek in?
Iantrek's product category is Ophthalmic Surgical Devices (Minimally Invasive Glaucoma Surgery). Its primary akta.pro industry code is HLAHAJAI, Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty), with a secondary code of HLAKAKAG, Glaucoma Specialists. Its NAICS code is 339115 and its SIC code is 3841.